UAE has arrived in Pakistan to conduct a feasibility study for a plan to build Pakistan’s first plasma farming facilities.
The field of plasma farming technologies is expanding in clinical medicine and patient care. It involves plasma fractionation, which is the separation of plasma fractions—individual proteins—from donor-obtained plasma.
In the prevention and treatment of life-threatening illnesses brought on by trauma, congenital deficits, immunologic disorders, or infections, protein products made from human plasma are frequently the only choice.
Sheikh Ahmed Dalmook Al-Maktoum served as the delegation’s leader, and it featured representatives of China’s Sinopharm, Emirati artificial intelligence firm Group 42, and Hayat Biotech Limited.
A blood product called fresh frozen plasma is created from the liquid fraction of whole blood. Low levels of other blood proteins or blood clotting factors are utilized to treat certain diseases. In plasma exchange, it might also serve as the replacement fluid.
The PFF project has been under development between Pakistan and the UAE for a while, and a Pakistani delegation visited the UAE in June, according to the minister.
In roughly two weeks, the UAE delegation will provide its report, and after that, “we will sign an agreement to cover its legal structure.”
Patel claimed that by eliminating the need to import various pricey drugs, the facilities will help Pakistan save valuable foreign currency.
“No country can sustain itself without working on plasma farming, as we import all the plasma-based treatments, which cost us millions of dollars in foreign currency,” he added, adding that plasma would also be freely available, especially for thalassemia, hepatitis, and cancer patients.
A genetic database profiling system was being discussed between Pakistan and the UAE as a way to modernize hospitals across the nation, digitalize the Pakistani health system, and improve staff training and medical equipment.